A pooled SPYRAL HTN analysis (n = 2,137) showed sustained blood pressure reductions through 3 years after Symplicity Spyral renal denervation. A separate pooled analysis found a 42% reduction in ...
Route 92 Medical, Inc. announced the commencement of the SUMMIT RISE postmarket study evaluating the performance of the company&rs ...
VS3 Medical, Inc. announced it has commenced enrollment in an international first-in-human (FIH) study evaluating the VS3 Med ...
Salus Scientific Corporation, a developer of radiation protection garments and clinical workflow solutions for fluoroscopy-guided ...
BD (Becton, Dickinson and Company) announced it has obtained CE Mark approval for the Revello vascular covered stent for the ...
VentureMed Group, Inc. announced it is now doing business as (DBA) Flex Vascular. The medical device company specializes in ...
Royal Philips announced the launch of Rembra, its next-generation radiology CT system designed for acute and high-demand imaging.
Spryte Medical announced the commencement of enrollment in the INSYTE trial evaluating the company’s neuro-optical CT (nOCT) ...
Otsuka Medical Devices Co., Ltd. and Otsuka Pharmaceutical Co., Ltd., announced the commercial launch of the Paradise ultrasound r ...
CereVasc, Inc. announced results from a prospective, multicenter, single-arm clinical study evaluating the safety and clinical ...
Quantum Surgical, a medical device company specializing in minimally invasive robotic-assisted cancer treatment, announced the ...
A clinical discussion on how the long-term findings of the ZILVERPASS study inform decision-making for challenging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results